Portal de investigación
Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology.
Fecha de publicación:
Fecha Ahead of Print:
Autores de INCLIVA
Participantes ajenos a INCLIVA
- Rossignol, P
- Voors, AA
- Mullens, W
- Metra, M
- Chioncel, O
- Januzzi, JL
- Mueller, C
- Richards, AM
- De Boer, RA
- Thum, T
- Arfsten, H
- Gonzalez, A
- Abdelhamid, M
- Adamopoulos, S
- Anker, SD
- Gal, TB
- Biegus, J
- Cohen-Solal, A
- Bohm, M
- Emdin, M
- Jankowska, EA
- Gustafsson, F
- Hill, L
- Jaarsma, T
- Jhund, PS
- Lopatin, Y
- Lund, LH
- Milicic, D
- Moura, B
- Piepoli, MF
- Ponikowski, P
- Rakisheva, A
- Ristic, A
- Savarese, G
- Tocchetti, CG
- Van Linthout, S
- Volterrani, M
- Seferovic, P
- Rosano, G
- Coats, AJS
- Bayes-Genis, A
Grupos y Plataformas de I+D+i
Abstract
Congestion is a cardinal sign of heart failure (HF). In the past, it was seen as a homogeneous epiphenomenon that identified patients with advanced HF. However, current evidence shows that congestion in HF varies in quantity and distribution. This updated view advocates for a congestive-driven classification of HF according to onset (acute vs. chronic), regional distribution (systemic vs. pulmonary), compartment of distribution (intravascular vs. extravascular), and clinical vs. subclinical. Thus, this review will focus on the utility of circulating biomarkers for assessing and managing the different fluid overload phenotypes. This discussion focused on the clinical utility of the natriuretic peptides, carbohydrate antigen 125 (also called mucin 16), bio-adrenomedullin and mid-regional pro-adrenomedullin, ST2 (also known as interleukin-1 receptor-like 1), cluster of differentiation 146, troponin, C-terminal pro-endothelin-1, and parameters of haemoconcentration. The utility of circulation biomarkers on top of clinical evaluation, haemodynamics, and imaging needs to be better determined by dedicated studies. Some multiparametric frameworks in which these tools contribute to management are proposed.
© 2022 European Society of Cardiology.
Datos de la publicación
- ISSN/ISSNe:
- 1388-9842, 1879-0844
- Tipo:
- Article
- Páginas:
- 1751-1766
- DOI:
- 10.1002/ejhf.2664
- PubMed:
- 36039656
EUROPEAN JOURNAL OF HEART FAILURE WILEY
Citas Recibidas en Web of Science: 97
Documentos
- No hay documentos
Filiaciones
Keywords
- Acute heart failure; Biomarkers; Congestion
Financiación
Proyectos y Estudios Clínicos
INCORPORACIÓN DE NUEVAS ÁREAS TEMÁTICAS Y NUEVOS GRUPOS AL CONSORCIO CIBER
Investigador Principal: JUAN SANCHIS FORES
CB16/11/00420 . INSTITUTO SALUD CARLOS III
Cita
Nunez J,de la Espriella R,Rossignol P,Voors AA,Mullens W,Metra M,Chioncel O,Januzzi JL,Mueller C,Richards AM,De Boer RA,Thum T,Arfsten H,Gonzalez A,Abdelhamid M,Adamopoulos S,Anker SD,Gal TB,Biegus J,Cohen A,Bohm M,Emdin M,Jankowska EA,Gustafsson F,Hill L,Jaarsma T,Jhund PS,Lopatin Y,Lund LH,Milicic D,Moura B,Piepoli MF,Ponikowski P,Rakisheva A,Ristic A,Savarese G,Tocchetti CG,Van S,Volterrani M,Seferovic P,Rosano G,Coats A,Bayes A. Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology. Eur. J. Heart Fail. 2022. 24. (10):p. 1751-1766. IF:18,200. (1).
Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology. Nunez J, de la Espriella R, Rossignol P, Voors AA, Mullens W, Metra M, Chioncel O et al. EUROPEAN JOURNAL OF HEART FAILURE. 2022 octubre 01. 24 (10):1751-1766. DOI:10.1002/ejhf.2664. PMID:36039656.
